Progress in controlling emesis with cancer chemotherapy

Richard J. Gralla, Rebecca A. Clark

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Marked progress in supportive care in cancer, and in control of chemotherapy-induced emesis in particular, has been accomplished over the past several years. Several effective antiemetic agents and regimens have been tested and are widely available. Emesis due to chemotherapy can now be completely controlled in the majority of patients. Progress in both clinical trials and in neuropharmacology has resulted in a new class of agents, the serotonin antagonists. These agents have an excellent therapeutic index and are well suited for a variety of clinical settings. Problems remain especially in the control of delayed emesis, in patients given several days of chemotherapy, and in radiation-induced emesis. Achieving the best antiemetic control, and at the same time having cost-effective therapy, is an ongoing challenge.

Original languageEnglish (US)
Pages (from-to)178-181
Number of pages4
JournalSupportive Care in Cancer
Issue number4
StatePublished - Jul 1 1993


  • 5-Hydroxytryptamine receptors
  • Antiemetics
  • Serotonin antagonists

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Progress in controlling emesis with cancer chemotherapy'. Together they form a unique fingerprint.

Cite this